









Humber Area Prescribing Committee

Summary of decisions made regarding new product requests considered at a meeting of the Committee on February 2023

Classification of products:

Status	Description
 GREEN	Medicines suitable for routine use within primary care and Secondary care. May be initiated within primary care within their licensed indication, in accordance with nationally recognised formularies
 AMB 1	Specialist recommendation: These medicines are considered suitable for GP prescribing following specialist recommendation or via an APC approved prescribing guideline.
 AMB 2	Specialist initiation: These medicines are considered suitable for GP prescribing following specialist initiation, including titration of dose and assessment of efficacy. These medicines may also have an APC approved guideline to aid GPs in further prescribing.
 AMB SCP	AMBER SHARE CARE PROTOCOL- Specialist initiation with ongoing monitoring: Medicines that must be initiated by a specialist, and which require significant monitoring on an ongoing basis. Full agreement to share the care of each specific patient must be reached under the shared care protocol which must be provided to the GP. If a commissioned shared care is not available in CCG/place then these drugs must be treated as red drug (hospital only).
 RED	Red-Hospital initiation and continuation only
 GREY	GREY- NON FORMULARY (As agreed by Area Prescribing Committee)
 PURPLE	To be supplied from the appropriate commissioned provider.
 NR	Not routinely commissioned

Product	Decision			Comments/notes
	Approved	Refused	Deferred	
1) Requests deferred from previous meetings				
Nil				
2) New Requests				
Nil this month				
3) New formulations & extensions to use				
Melatonin (Adaflex)	AMB SCP			SCF for Hull and East Riding of Yorkshire. Already used in acute trusts for a hospital only indication.
Tenecteplase	RED			For use in acute stroke (large vessel occlusion)

Product	Decision			Comments/notes
	Approved	Refused	Deferred	
Upadacitinib	RED			As per NICE guidance for ulcerative colitis and for compassionate use in Crohn's disease.
4) Products considered by NICE				
TA838: Slow-release potassium bicarbonate–potassium citrate for treating distal renal tubular acidosis (terminated appraisal) Commissioning: NHSE	NR			The formulary will reflect the TAG – NHS England is the responsible commissioner.
TA839: Ruxolitinib for treating acute graft versus host disease refractory to corticosteroids (terminated appraisal) Commissioning: NHSE	NR			The formulary will reflect the TAG – NHS England is the responsible commissioner.
TA840: Ruxolitinib for treating chronic graft versus host disease refractory to corticosteroids (terminated appraisal) Commissioning: NHSE	NR			The formulary will reflect the TAG – NHS England is the responsible commissioner.
TA841: Carfilzomib with daratumumab and dexamethasone for treating relapsed or refractory multiple myeloma (terminated appraisal) Commissioning: NHSE	NR			The formulary will reflect the TAG – NHS England is the responsible commissioner.
TA843: Luspatercept for treating anaemia caused by beta-thalassaemia (terminated appraisal)	NR			The formulary will reflect the TAG – NHS England is the responsible commissioner.
TA844: Luspatercept for treating anaemia caused by myelodysplastic syndromes (terminated appraisal)	NR			The formulary will reflect the TAG – NHS England is the responsible commissioner.
TA845: Mepolizumab for treating eosinophilic granulomatosis with polyangiitis (terminated appraisal)	NR			The formulary will reflect the TAG – NHS England is the responsible commissioner.

Product	Decision			Comments/notes
	Approved	Refused	Deferred	
TA846: Mepolizumab for treating severe hypereosinophilic syndrome (terminated appraisal)	NR			The formulary will reflect the TAG – NHS England is the responsible commissioner.
TA847: Mepolizumab for treating severe chronic rhinosinusitis with nasal polyps (terminated appraisal)	NR			The formulary will reflect the TAG – NHS England is the responsible commissioner.
TA848: Cemiplimab for untreated PD-L1-positive advanced or metastatic non-small-cell lung cancer (terminated appraisal) Commissioning: NHSE	NR			The formulary will reflect the TAG – NHS England is the responsible commissioner.
TA849: Cabozantinib for previously treated advanced hepatocellular carcinoma Commissioning: NHSE	RED			The formulary will reflect the TAG – NHS England is the responsible commissioner.
TA850: Amivantamab for treating EGFR exon 20 insertion mutation-positive advanced non-small-cell lung cancer after platinum-based chemotherapy	NR			The formulary will reflect the TAG – NHS England is the responsible commissioner.
TA851: Pembrolizumab for neoadjuvant and adjuvant treatment of triple-negative early or locally advanced breast cancer	RED			The formulary will reflect the TAG – NHS England is the responsible commissioner.
TA852: Trifluridine–tipiracil for treating metastatic gastric cancer or gastro-oesophageal junction adenocarcinoma after 2 or more treatments Commissioning: NHSE	RED			The formulary will reflect the TAG – NHS England is the responsible commissioner.
TA853: Avatrombopag for treating primary chronic immune thrombocytopenia	RED			The formulary will reflect the TAG – ICS is the responsible commissioner.

Product	Decision			Comments/notes
	Approved	Refused	Deferred	
TA854: Esketamine nasal spray for treatment-resistant depression	NR			
5) Appeals against earlier decisions by the APC				
None				
6) Miscellaneous formulary decisions by the APC				
Pilocarpine eye drops	AMB 2			Updated classification

The following guidelines were presented to and approved at the February 2023 meeting of the APC:

- Red drug guidance for nintedanib
- Red drug guidance for pirfenidone
- Amber 1 drug guidance for fidaxomicin
- Amber 1 drug guidance for fosfomycin
- Amber 1 drug guidance for pivmecillinam
- Upper respiratory tract guidance (Hull and ERY only)
- Wound management formulary CHCP (Hull and ERY)

The following drug information leaflets were presented to and approved at the February 2023 meeting of the APC:

- Nil

The following shared care guidelines were presented to and approved at the February 2023 meeting of the APC:

- Nil

Other documents presented to and approved at the February 2023 meeting of the APC:

- Nil